Article
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Cancer discovery - 1 Apr 2018
Annala Matti, Vandekerkhove Gillian, Khalaf Daniel, Taavitsainen Sinja, Beja Kevin, Warner Evan W, Sunderland Katherine, Kollmannsberger Christian, Eigl Bernhard J, Finch Daygen, Oja Conrad D, Vergidis Joanna, Zulfiqar Muhammad, Azad Arun A, Nykter Matti, Gleave Martin E, Wyatt Alexander W, Chi Kim N
Abstract excerpt
Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with treatment-naïve mCRPC to abiraterone or enzalutamide and performed whole-exome and deep targeted 72-gene sequencing of plasma cell-free DNA prior to therapy. For these agents, which have never been directly compared, time to progression...
Topics
Join the communities discussing this publication.